Proteases are potential targets for treatment of cardiovascular, cancer, inflammatory diseases and neurological disorders. Protease activity is tightly controlled in the biological system. Either too little or too much proteolysis can cause health problems. Although drugs for blocking excessive proteolysis are widely explored to treat chronic diseases, failures in the development emphasize the importance of maintaining balanced proteolysis in protease-targeted therapy.
Theramix develops imaging techniques that detect expression and activity of proteases to guide the development of drugs targeting proteases. We use protease activity imaging to screen drug targets, and to evaluate the drug engagement and efficacy. The validated imaging techniques will be translated to clinic to identify patients for protease-targeted treatment and monitor the treatment response.
